BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy. World J Gastroenterol 2017; 23(34): 6197-6200 [PMID: 28974885 DOI: 10.3748/wjg.v23.i34.6197]
URL: https://www.wjgnet.com/1007-9327/full/v23/i34/6197.htm
Number Citing Articles
1
C.R.H. Hedin, E. Sonkoly, M. Eberhardson, M. Ståhle. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approachJournal of Internal Medicine 2021; 290(2): 257 doi: 10.1111/joim.13282
2
Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos. The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical TrialsJournal of Clinical Medicine 2022; 11(11): 3045 doi: 10.3390/jcm11113045
3
Jeroen Geldof, Nusrat Iqbal, Janindra Warusavitarne, Ailsa Hart. The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CDClinics in Colon and Rectal Surgery 2022; 35(01): 021 doi: 10.1055/s-0041-1740035
4
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologicsGastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
5
Wan-Ting Cao, Rong Huang, Ke-Fang Jiang, Xue-Hui Qiao, Jing-Jing Wang, Yi-Hong Fan, Yi Xu. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic reviewWorld Journal of Gastroenterology 2021; 27(9): 886-907 doi: 10.3748/wjg.v27.i9.886
6
Jeroen Geldof, Nusrat Iqbal, Jean-Frédéric LeBlanc, Sulak Anandabaskaran, Rachel Sawyer, Christianne Buskens, Willem Bemelman, Krisztina Gecse, Lilli Lundby, Amy L Lightner, Silvio Danese, Antonino Spinelli, Michele Carvello, Omar Faiz, Janindra Warusavitarne, Phillip Lung, Danny De Looze, André D'Hoore, Séverine Vermeire, Ailsa Hart, Phil Tozer. Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trialsThe Lancet Gastroenterology & Hepatology 2022; 7(6): 576 doi: 10.1016/S2468-1253(22)00007-3
7
Ye Ma, Runfeng Zhang, Wei Liu, Yinghao Sun, Jingnan Li, Hong Yang, Hong Lv, Yue Li, Bei Tan, Xiyu Sun, Jiaming Qian, Ji Li. Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s diseaseBMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02676-9
8
Na Hong, Wei-Yong Liu, Jin-Long Zhang, Kai Qian, Jie Liu, Xian-Jun Ye, Fei-Yan Zeng, Yue Yu, Kai-Guang Zhang. Assessment of perianal fistulizing Crohn’s disease activity with endoanal ultrasound: A retrospective cohort studyWorld Journal of Gastrointestinal Surgery 2024; 16(8): 2494-2502 doi: 10.4240/wjgs.v16.i8.2494
9
Konstantinos Papamichael, Niels Vande Casteele, Jenny Jeyarajah, Vipul Jairath, Mark T. Osterman, Adam S. Cheifetz. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc AnalysisAmerican Journal of Gastroenterology 2021; 116(5): 1007 doi: 10.14309/ajg.0000000000001111